ORCHID PHARMA Share Price
ORCHID PHARMA Share Price Today
As of 3 Sep 2026, ORCHID PHARMA share price is ₹942.00. The stock opened at ₹936.00, compared to its previous close of ₹938.05. During today's trading session, ORCHID PHARMA share price moved in the range of ₹933.40 to ₹954.75, with an average price of ₹944.08 for the day. Looking at its last 52-week, the stock has touched a low of ₹480.00 and a high of ₹1,133.00. On the performance front, ORCHID PHARMA share price has increased by 56.32% over the last six months and is up 27.57% on a year-on-year basis.
ORCHID PHARMA Returns Calculator
About ORCHID PHARMA
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
ORCHID PHARMA Financial Highlights
- Revenue: ORCHID PHARMA reported revenue of ₹1,269.20 crore in FY26 vs ₹949.40 crore in FY25. It showed an increase of 33.68% on a yearly basis.
- Operating Profit: ORCHID PHARMA reported an operating profit of ₹10.43 crore in FY26 vs ₹95.56 crore in FY25. It showed a decrease of 89.09% on a year-on-year basis.
- Net Profit: ORCHID PHARMA reported a net profit of ₹10.62 crore in FY26 vs ₹95.76 crore in FY25. It showed a decrease of 88.91% on a yearly basis.
ORCHID PHARMA Quarterly Result Highlights
- ORCHID PHARMA reported revenue of ₹306.00 crore in Jun 2026, compared with ₹376.10 crore in Mar 2026, representing a decrease of 18.64% on a quarter-on-quarter (QoQ) basis.
- ORCHID PHARMA reported an operating profit of ₹2.65 crore in Jun 2026, compared with ₹24.85 crore in Mar 2026, representing a decrease of 89.34% on a quarter-on-quarter (QoQ) basis.
- ORCHID PHARMA reported a profit of ₹2.58 crore in Jun 2026, compared with ₹24.84 crore in Mar 2026, reflecting a decrease of 89.61% on a QoQ basis.
- The earnings per share (EPS) of ORCHID PHARMA stood at ₹19.65 during Jun 2026.
| Sep 2025 | 1.56% |
|---|---|
| Dec 2025 | 1.17% |
| Mar 2026 | 0.87% |
| Jun 2026 | 0.81% |
ORCHID PHARMA Shareholder Returns
ORCHID PHARMA Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,63,791.00 | 38.28 | 5.55 | 13.74% | 0.61 | 17.33% | 93.24 | 0.83% | 0.48 | 10.90 |
| Divis Laboratories | 2,45,081.00 | 83.79 | 14.62 | 15.32% | 0.00 | 19.56% | 629.49 | 0.32% | 0.55 | 98.19 |
| Torrent Pharmaceuticals | 1,90,351.00 | 88.29 | 22.64 | 25.49% | 1.69 | 13.85% | 222.76 | 0.68% | 0.49 | 58.70 |
| Zydus Lifesciences | 1,16,114.00 | 25.00 | 4.24 | 18.59% | 0.31 | 17.35% | 237.30 | 0.09% | 0.33 | 35.38 |
| Cipla | 1,14,554.00 | 34.02 | 3.32 | 11.27% | 0.00 | 14.95% | 423.36 | 0.92% | 0.45 | 43.52 |
| Laurus Labs | 1,00,660.00 | 92.32 | 18.99 | 16.77% | 0.40 | 16.14% | 97.20 | 0.11% | 0.67 | 13.72 |
| Lupin | 98,312.20 | 17.73 | 4.38 | 23.76% | 0.04 | 24.88% | 659.00 | 0.84% | 0.57 | 129.18 |
| Dr. Reddy's Laboratories | 96,906.30 | 30.44 | 2.55 | 11.07% | 0.18 | 12.54% | 377.95 | 0.69% | 0.41 | 38.68 |
| Mankind Pharma | 97,467.00 | 47.54 | 6.03 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.44 | 49.37 |
| Aurobindo Pharma | 95,299.80 | 25.68 | 2.52 | 9.25% | 0.19 | 11.76% | 394.82 | 0.24% | 0.38 | 41.58 |
ORCHID PHARMA Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹921.93 | ₹819.37 | ₹665.90 | ₹559.56 |
| Other Income | ₹27.47 | ₹30.86 | ₹19.43 | ₹9.00 |
| Total Revenue | ₹949.40 | ₹850.23 | ₹685.33 | ₹568.56 |
| Total Expenses | ₹853.84 | ₹758.29 | ₹669.29 | ₹625.46 |
| Profit Before Tax | ₹95.56 | ₹91.95 | ₹55.25 | -₹56.90 |
| Tax | -₹0.19 | -₹3.12 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹95.76 | ₹95.06 | ₹55.25 | -₹56.90 |
| EPS - Basic | ₹19.65 | ₹19.06 | ₹11.35 | -₹0.48 |
| EPS - Diluted | ₹19.65 | ₹19.06 | ₹11.35 | -₹0.48 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹99.46 | ₹89.05 | ₹46.32 | -₹1.95 |
| Income before WC changes | ₹128.69 | ₹133.20 | ₹97.70 | ₹34.81 |
| Change in Assets | -₹105.00 | -₹55.43 | -₹87.17 | ₹5.69 |
| Change in Liabilities | -₹3.54 | ₹47.59 | ₹8.10 | ₹53.87 |
| Change in WC | -₹108.53 | -₹7.84 | -₹79.06 | ₹59.57 |
| Cash flow from Operations | ₹19.22 | ₹125.99 | ₹18.34 | ₹92.47 |
| Cash flow from Investing | -₹26.93 | -₹312.03 | -₹31.21 | ₹112.94 |
| Cash flow from Financing | ₹25.22 | ₹167.04 | ₹31.17 | -₹216.80 |
| Total Cash Flow | ₹17.51 | -₹19.00 | ₹18.29 | -₹11.39 |
| Cash (Start of the year) | ₹3.60 | ₹22.60 | ₹4.31 | ₹15.69 |
| Cash (End of the year) | ₹21.11 | ₹3.60 | ₹22.60 | ₹4.31 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹880.50 | ₹763.12 | ₹724.20 | ₹712.91 |
| Current Assets | ₹807.42 | ₹790.75 | ₹501.01 | ₹397.65 |
| Total Assets | ₹1,687.91 | ₹1,553.87 | ₹1,225.21 | ₹1,110.56 |
| Current Liabilities | ₹285.57 | ₹259.97 | ₹371.89 | ₹240.78 |
| Net Current Asset | ₹521.85 | ₹530.78 | ₹129.12 | ₹156.87 |
| Non-Current Liabilities | ₹135.06 | ₹124.43 | ₹164.67 | ₹222.40 |
| Equity Capital | ₹1,267.29 | ₹1,169.47 | ₹688.65 | ₹647.38 |
| Total Equity & Liabilities | ₹1,687.91 | ₹1,553.87 | ₹1,225.21 | ₹1,110.56 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹921.93 | ₹819.37 | ₹665.90 | ₹556.97 |
| Other Income | ₹31.93 | ₹30.39 | ₹19.43 | ₹9.00 |
| Total Revenue | ₹953.86 | ₹849.76 | ₹685.33 | ₹565.98 |
| Total Expenses | ₹847.37 | ₹758.23 | ₹669.29 | ₹618.75 |
| Profit Before Tax | ₹106.48 | ₹91.52 | ₹55.25 | -₹52.77 |
| Tax | ₹0.00 | -₹3.23 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹106.48 | ₹94.75 | ₹55.25 | -₹52.77 |
| EPS - Basic | ₹20.99 | ₹19.59 | ₹13.28 | -₹1.18 |
| EPS - Diluted | ₹20.99 | ₹19.59 | ₹13.28 | -₹1.18 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹106.48 | ₹91.52 | ₹54.19 | -₹4.81 |
| Income before WC changes | ₹130.01 | ₹133.21 | ₹108.29 | ₹33.43 |
| Change in Assets | -₹100.25 | -₹45.55 | -₹104.38 | ₹9.91 |
| Change in Liabilities | -₹1.33 | ₹42.33 | ₹9.78 | ₹48.13 |
| Change in WC | -₹101.58 | -₹3.22 | -₹94.60 | ₹58.04 |
| Cash flow from Operations | ₹27.48 | ₹130.73 | ₹13.39 | ₹89.57 |
| Cash flow from Investing | -₹37.35 | -₹315.81 | -₹26.70 | ₹112.93 |
| Cash flow from Financing | ₹25.44 | ₹167.07 | ₹31.17 | -₹216.80 |
| Total Cash Flow | ₹15.58 | -₹18.01 | ₹17.86 | -₹14.30 |
| Cash (Start of the year) | ₹0.29 | ₹18.31 | ₹0.45 | ₹14.75 |
| Cash (End of the year) | ₹15.87 | ₹0.29 | ₹18.31 | ₹0.45 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹910.19 | ₹769.91 | ₹729.46 | ₹711.12 |
| Current Assets | ₹786.39 | ₹782.29 | ₹493.79 | ₹383.07 |
| Total Assets | ₹1,696.58 | ₹1,552.20 | ₹1,223.26 | ₹1,094.19 |
| Current Liabilities | ₹237.47 | ₹209.67 | ₹326.63 | ₹193.83 |
| Net Current Asset | ₹548.92 | ₹572.62 | ₹167.16 | ₹189.24 |
| Non-Current Liabilities | ₹135.06 | ₹124.21 | ₹164.67 | ₹222.40 |
| Equity Capital | ₹1,324.05 | ₹1,218.32 | ₹731.96 | ₹677.95 |
| Total Equity & Liabilities | ₹1,696.58 | ₹1,552.20 | ₹1,223.26 | ₹1,094.19 |
| 3 Sep | 0L |
|---|---|
| 2 Sep | 0L |
| 1 Sep | 0L |
| 31 Aug | 0L |
| 28 Aug | 0L |
| 27 Aug | 1L |
| Average | 0L |
Popular Stocks
ORCHID PHARMA Share Price FAQs
What is ORCHID PHARMA share price today?
ORCHID PHARMA share price is ₹942.00 as on 03 Sep, 2026, 10:47 IST.
How has the ORCHID PHARMA share price performed in the past?
In the last 1 year, ORCHID PHARMA delivered a return of 27.57%. The ORCHID PHARMA share price hit a high of ₹1,133.00 and low of ₹480.00.
How much is the Mutual Fund shareholding in ORCHID PHARMA shares?
The Mutual Fund Shareholding in ORCHID PHARMA was 19.93% at the end of Jun 2026.
What is the the 52-week high and low of ORCHID PHARMA shares ?
The 52-week high and low of ORCHID PHARMA share is ₹1,133.00 and ₹480.00 as of 03 Sep, 2026.
What is the market cap of ORCHID PHARMA?
The market capitalisation of ORCHID PHARMA is ₹5,661.55 Crores as on 03 Sep, 2026.
What are the stock symbols of ORCHID PHARMA?
The stock symbol of ORCHID PHARMA is ORCHPHARMA on the NSE, 524372 on the BSE, and the ISIN is INE191A01027.
What was yesterday's closing price of ORCHID PHARMA shares ?
ORCHID PHARMA shares closed yesterday at ₹938.05 on NSE & ₹938.50 on BSE
How to buy ORCHID PHARMA shares?
To buy ORCHID PHARMA shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy ORCHID PHARMA shares on Holidays?
No, shares of ORCHID PHARMA or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell ORCHID PHARMA shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of ORCHID PHARMA?
The PE and PB ratio of ORCHID PHARMA is 524.3 and 4.33 respectively, as on 03 Sep, 2026, 10:47 IST.